Cell therapies for acute and chronic traumatic brain injury

Abstract Traumatic brain injury (TBI) is a global health problem, for which there are no approved therapies. Advances in acute clinical care have improved post-TBI survival, yet many patients are left with chronic TBI-related disabilities (i.e. chronic TBI). Existing treatments that focus on rehabilitation and symptom management do not modify the disease and have limited effectiveness. Consequently, chronic TBI-related disabilities remain a significant unmet medical need. Cell therapies have neuroprotective and neurorestorative effects which are believed to modify the disease. In this article, we review the safety and efficacy of cell therapies in early-phase clinical studies that have shown potential to improve outcomes in acute to chronic phases of TBI.

[1]  J. Ghajar,et al.  In Reply: Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations. , 2020, Neurosurgery.

[2]  S. Kuroda,et al.  Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke , 2020, International journal of molecular sciences.

[3]  A. Sharma,et al.  Autologous bone marrow mononuclear cell transplantation in patients with chronic traumatic brain injury- a clinical study , 2020, Cell Regeneration.

[4]  D. Kondziolka,et al.  Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. , 2019, Journal of neurosurgery.

[5]  M. Kameda,et al.  Cell therapy for central nervous system disorders: Current obstacles to progress , 2019, CNS neuroscience & therapeutics.

[6]  B. Amatya,et al.  Clinical practice guidelines for rehabilitation in traumatic brain injury: a critical appraisal , 2019, Brain injury.

[7]  Ruben G. L. Real,et al.  Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research , 2017, The Lancet Neurology.

[8]  P. Azouvi,et al.  Disability and Health Consequences of Traumatic Brain Injury: National Prevalence , 2017, American journal of physical medicine & rehabilitation.

[9]  N. Stocchetti,et al.  Rethinking Neuroprotection in Severe Traumatic Brain Injury: Toward Bedside Neuroprotection , 2017, Front. Neurol..

[10]  P. Dash,et al.  Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells , 2017, Stem cells.

[11]  Odette A. Harris,et al.  Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition , 2016, Neurosurgery.

[12]  E. Barbier,et al.  Cell-based therapy for traumatic brain injury. , 2015, British journal of anaesthesia.

[13]  D. van Klaveren,et al.  Health-related quality of life after TBI: a systematic review of study design, instruments, measurement properties, and outcome , 2015, Population Health Metrics.

[14]  Alok Sharma,et al.  Cell therapy attempted as a novel approach for chronic traumatic brain injury – a pilot study , 2015, SpringerPlus.

[15]  C. Cox,et al.  Autologous Bone Marrow Mononuclear Cells Reduce Therapeutic Intensity for Severe Traumatic Brain Injury in Children* , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[16]  Hongbing Cheng,et al.  Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury , 2013, Brain Research.

[17]  Cathy C. Y. Chou,et al.  A Standardized Approach to the Fugl-Meyer Assessment and Its Implications for Clinical Trials , 2013, Neurorehabilitation and neural repair.

[18]  Xiongwei Wang,et al.  Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture. , 2013, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[19]  Shanthi Ameratunga,et al.  Incidence of traumatic brain injury in New Zealand: a population-based study , 2013, The Lancet Neurology.

[20]  K. Hasan,et al.  Autologous Bone Marrow Mononuclear Cell Therapy for Severe Traumatic Brain Injury in Children , 2011, Neurosurgery.

[21]  J. Langlois,et al.  The Epidemiology and Impact of Traumatic Brain Injury: A Brief Overview , 2006, The Journal of head trauma rehabilitation.

[22]  O. Poveschenko,et al.  Cell transplantation therapy in re-animating severely head-injured patients. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  Ross Zafonte,et al.  Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. , 2005, Journal of neurosurgery.

[24]  S. Black,et al.  The Fugl-Meyer Assessment of Motor Recovery after Stroke: A Critical Review of Its Measurement Properties , 2002, Neurorehabilitation and neural repair.

[25]  D. Cifu,et al.  Acute predictors of successful return to work 1 year after traumatic brain injury: a multicenter analysis. , 1997, Archives of physical medicine and rehabilitation.

[26]  Carl V. Granger,et al.  Advances in functional assessment for medical rehabilitation , 1986 .

[27]  A. Fugl-Meyer,et al.  The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. , 1975, Scandinavian journal of rehabilitation medicine.

[28]  London Ps.  Some observations on the course of events after severe injury of the head. Hunterian Lecture delivered at the Royal College of Surgeons of England on12th January 1967. , 1967 .

[29]  T. Bleck.  Historical aspects of critical care and the nervous system. , 2009, Critical care clinics.

[30]  Qi Zhang,et al.  A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. , 2008, Cytotherapy.